Acute Porphyria Drug Database

N05AD01 - Haloperidol
Propably not porphyrinogenic
PNP

Rationale
No data pointing to CYP-induction. Repeatedly used in acute porphyria without ill effects. Several references state non-porphyrinogenicity.
Chemical description
(To be edited, initial data ST OCT 04) Butyrphenone low-dose neuroleptic used in psychotic conditions (e.g.in paranoia), also in childhood. Used in confusion states in elderly and against vomiting, e.g. in radiation sickness. Extensively metabolized, CYPs probably involved. No data pointing to CYP-inducing properties. Australian list: safe (conflicting evidence) EPI-list: safe South African list: use French list: use Martindale: Haloperidol is considered to be safe in patients with porphyria although there is conflicting experimental evidence of porphyrinogenicity.
IPNet drug reports
Uneventful use reported in 3 patients with acute porphyria.

Similar drugs
Explore alternative drugs in similar therapeutic classes N05A / N05AD or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙